Business
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
ALAMEDA, Calif.--(BUSINESS WIRE)-- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing
About this update from Vivani Medical, Inc.
[{"type":"text","content":" ALAMEDA, Calif.--(BUSINESS WIRE)--\nVivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York.\n\n\nVivani’s Chief Executive Officer, Adam Mendelsohn, Ph.D., will host one-on-one meetings with investors at the Conference in addition to providing an overview of the Company. Details of this presentation are as follows:\n\n\nDate: Wednesday, September 11, 2024\nTime: 10-10:30 a.m. Eastern Time\nLocation: Adams Room (Fourth floor), Lotte New York Palace, New York, NY\n\n\nThe Company presentation will be available via webcast starting at 10 a.m. ET on September 11 at the following link: https://journey.ct.events/view/a00c80c3-0668-4058-b4ca-4aad48978600.\n\n\nThe presentation will also be available on the Company’s website under the “News & Events” tab of the Vivani Investor page: https://investors.vivani.com/investors/news-events.\n\n\nAbout Vivani Medical, Inc.\n\n\nLeveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve tolerance to their medication. Vivani’s lead program, NPM-115, will evaluate a miniature, six-month, subdermal, GLP-1 (exenatide) implant for chronic weight management in obese or overweight patients. Vivani’s emerging pipeline also includes NPM-139 (semaglutide implant) which is also under development for chronic weight management in obese and overweight patients. NPM-139 has the added potential benefit of once-yearly administration. NPM-119 refers to the Company’s clinical program which will evaluate its six-month, subdermal exenatide implant for the treatment of type 2 diabetes. Both NPM-115 and NPM-119 will evaluate exenatide implants with a higher-dose associated with NPM-115 for chronic weight management in obese or overweight patients. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and in...